Report Sections

See All Reports

  • HP:0000020: Urinary incontinence
  • Pneumonia (312) Abnormality of the cardiovascular system (29) Neoplasm (27) Respiratory tract infection (27) Hypoxemia (22) Depressivity (21) Diabetes mellitus (19) Acute kidney injury (19) Abnormal lung morphology (19) Thromboembolism (17) Hypertension (16) Anosmia (14) Myocardial infarction (14) Abnormality of coagulation (14) Stroke (13) Pulmonary embolism (13) Arthritis (12) Leukemia (12) Interstitial pneumonitis (12) Autistic behavior (11) Mental deterioration (11) Deep venous thrombosis (10) Type II diabetes mellitus (10) Pulmonary obstruction (10) Crohn's disease (10) Abnormality of the kidney (9) Autism (9) Obesity (9) Congestive heart failure (9) Chronic pulmonary obstruction (9) Chronic pain (9) Rheumatoid arthritis (8) Abnormality of the liver (8) Respiratory distress (8) Pulmonary fibrosis (8) Colitis (8) Myocarditis (8) Carcinoma (8) Ulcerative colitis (8) Behavioral abnormality (7) Dementia (7) Infertility (7) Inflammation of the large intestine (7) Pulmonary insufficiency (7) Low levels of vitamin D (7) Neoplasm of the lung (7) Type I diabetes mellitus (7) Psychosis (6) Coronary artery atherosclerosis (6) Lymphoma (6) Abnormality of the gastrointestinal tract (6) Chronic kidney disease (6) Sepsis (6) Renal insufficiency (5) Lymphopenia (5) Gastroparesis (5) Immunodeficiency (5) Systemic lupus erythematosus (5) Breast carcinoma (5) Peripheral arterial stenosis (5) Allergy (5) Encephalopathy (4) Hepatic fibrosis (4) Cardiac arrest (4) Dysphagia (4) Asthma (4) Alzheimer disease (4) Osteoarthritis (4) Neoplasm of the pancreas (4) Autoimmunity (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Sleep apnea (4) Prostate cancer (4) Neoplasm of head and neck (4) Addictive behavior (4) Insomnia (4) Obsessive-compulsive behavior (3) Seizure (3) Cardiomyopathy (3) Weight loss (3) Fever (3) Migraine (3) Pulmonary arterial hypertension (3) Bronchiectasis (3) Obstructive sleep apnea (3) Colon cancer (3) Reduced factor VIII activity (3) Malnutrition (3) Knee osteoarthritis (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Arrhythmia (3) Fatigue (3) Endometriosis (3) Non-small cell lung carcinoma (3) Neuroendocrine neoplasm (3) Hypercoagulability (3) Schizophrenia (3) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormal heart morphology (2) Tachycardia (2) Angina pectoris (2) Gastroesophageal reflux (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Mutism (2) Headache (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Atherosclerosis (2) Hypoventilation (2) Myelodysplasia (2) Psoriasiform dermatitis (2) Paroxysmal atrial fibrillation (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Cystoid macular edema (2) Hemeralopia (2) Cutaneous melanoma (2) Arteritis (2) Glioblastoma multiforme (2) Cervix cancer (2) Pulmonary edema (2) Ovarian neoplasm (2) Angioedema (2) Mania (2) Neoplasm of the large intestine (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Hypogeusia (1) Conductive hearing impairment (1) Abnormality of the eye (1) Cataract (1) Amblyopia (1) Periodontitis (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Abnormality of the skin (1) Jaundice (1) Lymphedema (1) Angiokeratoma corporis diffusum (1) Keratoconjunctivitis (1) Spasticity (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic steatosis (1) Hepatic failure (1) Hepatocellular carcinoma (1) Premature birth (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Pancreatitis (1) Abnormality of blood and blood-forming tissues (1) Gout (1) Diarrhea (1) Anorexia (1) Esophageal varix (1) Hypothermia (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Encephalitis (1) Waddling gait (1) Increased intracranial pressure (1) Celiac disease (1) Biliary cirrhosis (1) Hypotension (1) Osteomyelitis (1) Squamous cell carcinoma (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Back pain (1) Low back pain (1) Muscular dystrophy (1) Neonatal death (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Coronary artery stenosis (1) Chronic lymphatic leukemia (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Abnormal anterior horn cell morphology (1) Amyotrophic lateral sclerosis (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Inflammatory abnormality of the skin (1) Sinus tachycardia (1) Bronchiolitis (1) Postprandial hyperglycemia (1) Hepatitis (1) Erythroid hypoplasia (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Small cell lung carcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Subdural hemorrhage (1) Endocarditis (1) Toxemia of pregnancy (1) Myositis (1) Vaginal neoplasm (1) Cellulitis (1) Self-injurious behavior (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0000020: Urinary incontinence

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (2)


    Name (Synonyms) Correlation
    drug3593 Urinary Incontinence Wiki 1.00
    drug3061 Sedentary behaviour Wiki 1.00

    Correlated MeSH Terms (2)


    Name (Synonyms) Correlation
    D014549 Urinary Incontinence NIH 1.00
    D004775 Enuresis NIH 1.00

    Correlated HPO Terms (1)


    Name (Synonyms) Correlation
    HP:0000805 Enuresis HPO 1.00

    Clinical Trials

    Navigate: Correlations   HPO

    There is one clinical trial.


    1 Associations Between Urinary Incontinence, Sedentary Behaviour and Other Health-related Outcomes in Nursing Homes in Catalonia: the OsoNaH Project

    The increase of the older adult population in the past years has generated an important impact on chronic conditions and geriatric syndromes like dementia, falls and urinary incontinence (UI). To better understand IU seems warranted because of its socioeconomic and health impact. Nursing home (NH) residents are the frailest segment of our population, with very low physical activity levels and highly sedentary. Several studies had shown that physical activity levels and time and patterns of sedentary behaviour (SB) are independent risk factors for many health issues. As far as the investigators know, there is no evidence supporting the relation between IU and SB, and no information about the incidence of IU in NH residents living in Catalonia (Spain). This project consists of two stages: stage 1 will conduct a cross-sectional study using mixed methodology (qualitative and quantitative), and a 2-year longitudinal study (stage 2). Stage 1 has the main objective of verifying the prevalence of IU and its associated factors in NH residents in Barcelona (Spain), as well as analyse the association between IU (and their types) with SB time and patterns. In addition, the proportion of geriatric residents who receive control measures for their IU, and whether they receive SB-related interventions from health professionals of the institution will be also explored. Finally, the investigators aim to understand the experience of NH residents and the health professionals who care for them about the characteristics, burden and barriers of having IU. Stage 2 has the main objective to verify the incidence of the functional and continence decline, falls, hospitalizations and mortality, as well as their predictive factors in older care/nursing home residents in Barcelona (Spain). Specific objetives are to assess the evolution of each activity of daily living and the causes of hospitalization and death in geriatrics residents for a period of 2 years and to verify the incidence of recurrent falls (one or more falls), and analyse the consequences of falls (fractures, hospitalizations, among others) among the residents. Potential risk and protective factors for mortality due to COVID-19 and its impact on functioning and hospitalizations will also be analyzed. Finally, the stage 2 of the project aims at creating a specific instrument for the evaluation of frailty in institutionalized older people, based on the main predictive factors of functional decline.

    NCT04297904
    Conditions
    1. Urinary Incontinence in Old Age
    2. Sedentary Behavior
    Interventions
    1. Behavioral: Sedentary behaviour
    2. Diagnostic Test: Urinary Incontinence
    MeSH:Urinary Incontinence Enuresis
    HPO:Enuresis Urinary incontinence

    Primary Outcomes

    Description: The presence of IU assessed by the Minimum Data Set (MDS) version 3.0

    Measure: Urinary Incontinence

    Time: January 2020 to July 2020 (cross-sectional)

    Description: Patterns of sedentary behaviour (SB) with monitors (PAL Technologies, Scotland).

    Measure: Patterns of sedentary behaviour

    Time: January 2020 to July 2020 (cross-sectional)

    Description: Modified (Likert 5-point scale) Barthel Index, assessed every 6 months

    Measure: Functional decline

    Time: January 2020 to January 2022 (longitudinal, follow-up)

    Description: Minimum Data Set (MDS) version 3.0, assessed every 6 months

    Measure: Continence decline

    Time: January 2020 to January 2022 (longitudinal, follow-up)

    Description: Prospective register of falls (date, place and consequence/s)

    Measure: Incidence of falls

    Time: January 2020 to January 2022 (longitudinal, follow-up)

    Description: Prospective register of hospitalizations (date and cause)

    Measure: Hospitalizations

    Time: January 2020 to January 2022 (longitudinal, follow-up)

    Description: Prospective register of deaths (date and cause)

    Measure: Mortality

    Time: January 2020 to January 2022 (longitudinal, follow-up)

    Secondary Outcomes

    Description: Sociodemographic variables (sex, age, civil status, education level, type of institution (public versus private / concerted) and time of residence in the institution.)

    Measure: Sociodemographic variables

    Time: January 2020 to July 2020

    Description: Number and proportion of participants with lower urinary tract symptoms with the International Prostate Symptoms Score and urinary infection for the last 30 days.

    Measure: Lower urinary tract symptoms

    Time: January 2020 to July 2020

    Description: Faecal incontinence according to Minimum Data Set version 3.0 (MDS 3.0)

    Measure: Faecal incontinence

    Time: January 2020 to July 2020

    Description: Diary

    Measure: Intake of liquids and diuretic drinks

    Time: January 2020 to July 2020

    Description: Dynamometer (2 trials per hand)

    Measure: Handgrip strength

    Time: January 2020 to July 2020

    Description: Short Physical Performance Battery (SPPB)

    Measure: Physical performance

    Time: January 2020 to July 2020

    Description: Rivermead Mobility Index

    Measure: Mobility

    Time: January 2020 to July 2020

    Description: Clinical Frailty Scale

    Measure: Frailty

    Time: January 2020 to July 2020

    Description: Modified (Likert 5-point scale) Barthel Index

    Measure: Basic activities of daily living

    Time: January 2020 to July 2020

    Description: What kind of physical activity programme, the frequency of the sessions weekly, the dose of exercise of each session, the duration of the whole session, who provides the session, where the session is performed and if the session is individually or in group).

    Measure: Physical activity programs

    Time: January 2020 to July 2020

    Description: What kind of programs are being applied to control and treat urinary and faecal incontinence in nursing homes

    Measure: Incontinence programs

    Time: January 2020 to July 2020

    Description: According to the Anatomical Therapeutic Chemical classification system and the Defined Daily Dose (ATC/DDD)

    Measure: Medication intake

    Time: January 2020 to July 2020

    Description: Number and proportion of participants with chronic diseases, delirium and pressure ulcers

    Measure: Health conditions

    Time: January 2020 to July 2020

    Description: European Quality of Life-5 Dimensions; final score for Spain ranges between 1 (full health) to -0.654 (worse outcome)

    Measure: Quality of life

    Time: January 2020 to July 2020

    Description: smoking and alcohol

    Measure: Toxic habits

    Time: January 2020 to July 2020

    Description: Pfeiffer Scale, with final score ranging from 0 (normal) to 10 (total cognitive impairment)

    Measure: Cognitive status

    Time: January 2020 to July 2020

    Description: 15-item Yesavage Geriatric Depression Scale, with final score ranging from 0 (normal) to 15 (severe depression)

    Measure: Depressive symptoms

    Time: January 2020 to July 2020

    Description: Hospital Anxiety and Depression Scale (HADS), with final score ranging from 0 (normal) to 21 (severe anxiety)

    Measure: Anxiety

    Time: January 2020 to July 2020

    Description: Using the NH register

    Measure: Number births

    Time: January 2020 to July 2020

    Description: Using the NH register

    Measure: Type of births

    Time: January 2020 to July 2020

    Description: During the last year, according to the NH register

    Measure: Number of falls

    Time: January 2020 to July 2020

    Description: Mini Nutritional Assessment Test, ranging from 0 (malnutrition) to 30 (normal)

    Measure: Nutritional status

    Time: January 2020 to July 2020

    Description: Amount of Vitamin D, albumin and pre-albumin, PCR (Protein C-Reactive) extracted from the routine analysis of the residents.

    Measure: Biochemical evaluation

    Time: January 2020 to July 2020

    Description: Percentage (%) of body fat, % of fat-free mass and % of body water assessed by a Tanita TBF-300 bioimpedance device

    Measure: Body composition

    Time: January 2020 to July 2020

    Description: Lubben Social Network Scale ranging from 0 to 30, with a higher score indicating more social engagement.

    Measure: Social network

    Time: January 2020 to July 2020

    Description: 6-item Gierveld Loneliness Scale ranging from 0 (not lonely) to 6

    Measure: Loneliness

    Time: January 2020 to July 2020

    Description: Date and result of diagnosis test/s for COVID-19 (PCR or serological antibody test)

    Measure: COVID-19

    Time: June 2020 to January 2022 (longitudinal, follow-up)

    Description: In the previous 6 months, the resident had symptoms compatible with COVID-19 (cough, fever and/or breathing difficulties) without COVID-19 diagnosis test confirmation

    Measure: Suspected case of COVID-19

    Time: June 2020 to January 2022 (longitudinal, follow-up)

    Description: Level of resident's frailty assessed with the Clinical Frailty Scale

    Measure: Frailty

    Time: June 2020 to January 2022 (longitudinal, follow-up)

    Description: Any change in the regular medication in the last 6 months (include the name of the med, dose and the duration of treatment)

    Measure: Change in medication

    Time: June 2020 to January 2022 (longitudinal, follow-up)

    HPO Nodes


    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook